- Home
- OP vs GLTO Comparison
OP vs GLTO Comparison
Compare OP & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- GLTO
- Stock Information
- Founded
- OP 2021
- GLTO 2011
- Country
- OP Greece
- GLTO Denmark
- Employees
- OP N/A
- GLTO N/A
- Industry
- OP
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- GLTO Health Care
- Exchange
- OP Nasdaq
- GLTO Nasdaq
- Market Cap
- OP 14.3M
- GLTO 4.5M
- IPO Year
- OP N/A
- GLTO 2020
- Fundamental
- Price
- OP $1.22
- GLTO $2.75
- Analyst Decision
- OP
- GLTO Buy
- Analyst Count
- OP 0
- GLTO 1
- Target Price
- OP N/A
- GLTO $10.00
- AVG Volume (30 Days)
- OP 1.1M
- GLTO 248.3K
- Earning Date
- OP 08-08-2025
- GLTO 10-31-2025
- Dividend Yield
- OP N/A
- GLTO N/A
- EPS Growth
- OP N/A
- GLTO N/A
- EPS
- OP N/A
- GLTO N/A
- Revenue
- OP $19,435,000.00
- GLTO N/A
- Revenue This Year
- OP N/A
- GLTO N/A
- Revenue Next Year
- OP N/A
- GLTO N/A
- P/E Ratio
- OP N/A
- GLTO N/A
- Revenue Growth
- OP N/A
- GLTO N/A
- 52 Week Low
- OP $1.07
- GLTO $2.01
- 52 Week High
- OP $79.25
- GLTO $14.56
- Technical
- Relative Strength Index (RSI)
- OP 32.09
- GLTO 37.74
- Support Level
- OP $1.19
- GLTO $2.53
- Resistance Level
- OP $1.21
- GLTO $3.99
- Average True Range (ATR)
- OP 0.09
- GLTO 0.31
- MACD
- OP 0.70
- GLTO -0.03
- Stochastic Oscillator
- OP 24.59
- GLTO 19.48
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.